BARD1 teams up with Institute for Respiratory Health to evaluate its cancer vaccine
Published 05-APR-2017 11:43 A.M.
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
BARD1 Life Sciences (ASX: BD1) announced on Tuesday that it had entered into a collaboration agreement with the Institute for Respiratory Health (IRH) in order to evaluate the company’s cancer vaccine for the prevention and/or treatment of cancer in animal models.
By way of background, BARD Life Sciences is an Australian biotechnology company focused on developing and commercialising non-invasive diagnostic tests for early detection of cancer. The group’s lead product, the BARD1 lung cancer test is a blood test in development for early detection of lung cancer, utilising novel tumour markers and a proprietary algorithm.
The company’s pipeline also includes the BARD1 Ovarian Cancer Test, which is in development for early detection of ovarian cancer, and high-value diagnostic and therapeutic projects at research stage for multiple cancers.
The collaboration agreement is an important development given that the Institute for Respiratory Health is supported by world-class researchers and dedicated clinicians who focus on investigating, diagnosing, treating and preventing respiratory conditions.
However, it should be noted here that this company represents a speculative investment and those considering this stock for their portfolio should seek professional financial advice before making a decision.
The project will evaluate various BARD1 formulations across several fully characterised tumour cell lines to determine their effectiveness in preventing tumour growth or reducing tumour size in two industry-accepted tumour models in mice.
It will also determine the optimal dose and timing for vaccination, as well as other secondary outcomes.
In fleshing out the key benefits of this collaboration agreement, BD1 Chief Executive, Doctor Learnne Hinch said, “We have already demonstrated the utility of this technology in the diagnostic area, but therapeutic applications offer a large upside potential and, if the animal studies demonstrate effectiveness, this collaboration will enable us to advance our therapeutic program towards preclinical development”.
Professor Geoff Laurent, director of the IRH provided a strong endorsement of BD1’s progress, saying, “We believes the BARD1 Technology has much to offer in the field of therapeutic vaccines for lung cancer, and this is precisely the kind of mutually beneficial research collaboration that if successful will expand the therapeutic options for cancer patients”.
BCC Research valued the global cancer vaccine market at US$3.5 billion in 2016.
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.